Apolipoprotein E genotyping for pharmacogenetic purposes in Alzheimer's disease: Emerging ethical issues

被引：14

作者：

Issa, AM ^{[1
]}

Keyserlingk, EW ^{[1
]}

机构：

[1] McGill Univ, Fac Med, Biomed Eth Unit, Montreal, PQ, Canada

来源：

CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE | 2000年 / 45卷 / 10期

关键词：

Alzheimer's disease; apolipoprotein E; bioethics; clinical research; genotyping; pharmacogenetics; research ethics;

D O I：

10.1177/070674370004501007

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Objective: To pr-ec ent some of the ethical concerns pertaining to the anticipated use of apolipoprotein E genotyping in selecting therapy in Alzheimer's disease. Method: We, review studies that support the utility of apolipoprotein E (APO E) genotyping for predicting drug responsiveness along,with the published consensus statements and position papers related to APO E genotyping. Ethical issues pertaining to the use of APO E genotyping for pharmacogenetic purposes have not yet been fully explored, and these are discussed. Results: This payer explores the bioethics surrounding the use of APO E genotyping for pharmacogenetic purposes. The rapidly increasing pace of clinical trials in Alzheimer's disease necessitates a critical examination of the evolving ethical issues. A framework for establishing guidelines is suggested Conclusions: Clinical research trials for Alzheimer's disease nifh a genotyping component will increasingly he influenced by and benefit from a serious analysis of the ethics emerging alongside the scientific and clinical advances.

引用

页码：917 / 922

页数：6

共 70 条

[1] Alzheimer's disease: a review of the disease, its epidemiology and economic impact [J].

Alloul, K ;

Sauriol, L ;

Kennedy, W ;

Laurier, C ;

Tessier, G ;

Novosel, S ;

Contandriopoulos, A .

ARCHIVES OF GERONTOLOGY AND GERIATRICS, 1998, 27 (03) :189-221

[2] PRIVACY RULES FOR DNA DATA-BANKS - PROTECTING CODED FUTURE DIARIES [J].

ANNAS, GJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (19) :2346-2350

[3]

[Anonymous], 1993, INT ETH GUID BIOM RE

[4] INCIDENCE OF DEMENTIA AND PROBABLE ALZHEIMERS-DISEASE IN A GENERAL-POPULATION - THE FRAMINGHAM-STUDY [J].

BACHMAN, DL ;

WOLF, PA ;

LINN, RT ;

KNOEFEL, JE ;

COBB, JL ;

BELANGER, AJ ;

WHITE, LR ;

DAGOSTINO, RB .

NEUROLOGY, 1993, 43 (03) :515-519

[5] Barriers to obtaining consent in dementia research: Implications for surrogate decision-making [J].

Baskin, SA ;

Morris, J ;

Ahronheim, JC ;

Meier, DE ;

Morrison, RS .

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1998, 46 (03) :287-290

[6]

BEAUCHAMP TL, 1994, PRINCIPLES BIOMEDICA, P142

[7]

BILLINGS PR, 1992, AM J HUM GENET, V50, P476

[8] APOLIPOPROTEIN-E GENOTYPING IN THE DIAGNOSIS OF ALZHEIMERS-DISEASE - A CAUTIONARY VIEW [J].

BIRD, TD .

ANNALS OF NEUROLOGY, 1995, 38 (01) :2-4

[9] The health care cost of drug-related morbidity and mortality in nursing facilities [J].

Bootman, JL ;

Harrison, DL ;

Cox, E .

ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (18) :2089-2096

[10]

Brodaty H, 1995, ALZ DIS ASSOC DIS, V9, P182

← 1 2 3 4 5 6 7 →